Form 4: Pfizer Director James Quincey Acquires Phantom Stock Units as Deferred Compensation

Pfizer director James Quincey acquired 1,460.611 phantom stock units as part of deferred compensation, which will be settled in cash or common stock upon retirement.

Summary

• James Quincey, a director at Pfizer Inc., acquired 1,460.611 phantom stock units on December 31, 2024.
• These units represent deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at Mr. Quincey's election following his retirement from the Board of Directors.
• The price of the underlying common stock at the time of the transaction was $26.53 per share.
• Following this transaction, Mr. Quincey beneficially owns 55,028.61 shares of Pfizer common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The deferred compensation structure may incentivize continued service on the board.

Future Outlook

The phantom stock units will be settled in cash or common stock upon the director's retirement, which is a future event.

Industry Context

This is a standard practice for compensating board members at large public companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Deferred compensation plans, including phantom stock units, are common among large pharmaceutical companies like Johnson & Johnson (JNJ) and Merck (MRK) to incentivize and retain board members.
• The use of phantom stock units is similar to stock options or restricted stock units, but they do not grant actual ownership until settlement, which is a common practice in executive compensation.
• The value of the units is tied to the company's stock price, which is a standard method for aligning director compensation with shareholder value.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with the company's long-term performance.
• The transaction has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Pfizer, Director, James Quincey, Phantom Stock Units, Deferred Compensation, Form 4, SEC Filing, Insider Trading